+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-09-08Number of Pages: 154

Radiodermatitis Market (Product type - Topical (Corticosteroids, Hydrophilic Creams, and Topical Antibiotics), Oral Medication (Corticosteroids, Oral Analgesics, Antibiotics), and Dressings (Hydrogel, Hydrocolloid, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressing (GM-CSF Gauze and Silver Leaf Dressing); By Distribution Channel - Hospital Pharmacy, Retail Pharmacy Store, and Online Store) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Radiodermatitis Market: Snapshot

The global radiodermatitis market has been witnessing a significant progress over the last few years on the grounds of the rising prevalence of cancer and the growing uptake of radiation therapy for its treatment. Thanks to the increasing focus on product innovations and advancements in existing products, the market is also showing high potential for future growth.

Over the coming years, the unmet medical needs of consumers in emerging regions is expected to open a plethora of growth opportunities for market players, leading to a substantial rise in this market. Expanding at a CAGR of 3.90% over the period from 2016 to 2024, the market, which stood at US$299.6 mn in 2015, is anticipated to increase to US$421.5 mn by the end of the forecast period.

radiodermatitis-market

 

Asia Pacific to Retain Leadership in Global Radiodermatitis Market

Spread across Asia Pacific, the Middle East and Africa, North America, Latin America, and Europe, the market for radiodermatitis boasts of a robust presence across the world. Asia Pacific, among all, has been leading the global radiodermatitis market, thanks to a higher percentage of patients eligible for radiotherapy. The increasing pool of cancer patients is expected to drive the Asia Pacific radiodermatitis market further, ensuring its dominance over the next few years. Since a number of Asian economies, situated in the tropical region, have humid weather conditions, the severity of radiation dermatitis is significantly high in this geographical segment, which is also expected to boost the market for radiodermatitis in Asia Pacific in the near future.

Amongst other regional markets for radiodermatitis, Europe also possesses a considerable share in the global market on account of the increase in research and development activities in life sciences, upswing in academic research in radiation dermatitis, and the escalating number of product launches in this region. The market in North America has been driven by the presence of a large pool of well-established pharmaceutical enterprises, research organizations, and several government institutes, which actively work on developing a standard treatment solution for radiodermatitis.

Latin America and the Middle East and Africa are likely to gain considerably from the increasing attention of multinational companies on them. The large base of the unprivileged population, particularly in the Middle East and central Africa, and the implementation of new policies encouraging the uptake of radiotherapy in these regions are anticipated to boost the radiodermatitis markets in Latin America and the Middle East and Africa.

Topical Agents to Continue Being Most Valued Radiodermatitis Products

Topical, oral medication, and dressings are the main products available in the global market for radiodermatitis. Topical agents witness a higher demand from end users than other radiodermatitis products and are anticipated to continue doing so over the next few years. The ease of availability and cost benefits of topical products have fueled their demand among all strata of consumers, which is likely to reflect positively on their sales in the near future.

Corticosteroid creams, hydrophilic creams, and topical antibiotics are most preferred topical products across the world. Hydrophilic creams report a much higher demand than the other two. Analysts expect this scenario to remain so over the years to come.

Stratpharma AG, Smith & Nephew Plc, Molnlycke Health Care, Intermed Pharmaceuticals, Derma Sciences Inc., ConvaTec Inc., BMG Pharma S.r.l., Acelity LP Inc., and 3M are the key participants in the global Radiodermatitis market.

Global Radiodermatitis Market: Overview

Radiodermatitis, also known as radiation dermatitis, is a peculiar symptom caused as a result of radiation therapy pertaining to the treatment of cancerous as well as noncancerous conditions, and has significant negative impact on a patient’s physical functionalities and quality of life. It has been estimated that in developed countries such as the U.S., Canada, Australia, the U.K, France, and Germany, nearly half of the patients who receive treatment for cancer was also subjected to radiation therapy during the illness, and about all of them experience some degree of skin reaction. As the cases of cancer escalates across the world, the demand in the global radiodermatitis is expected to increment at a considerable CAGR of 3.90% during the forecast period of 2016 to 2024. 

This report on the global radiodermatitis market estimates the valuation of the market to swell up to US$421.5 mn by the end of 2024, increasing from its evaluated worth of US$299.6 mn in 2015. This report, developed by a group of professional market research analysts, aspires to serve as a credible business tool for the stakeholders of this market. The report studies the prospects of various segments of the market, based on product, distribution channel, and geography, as well as profiles a number of leading players to understand the competitive landscape. Qualitative and quantitative assessment of all factors that may influence the demand for radiodermatitis has been provided in the report. 

Global Radiodermatitis Market: Trends & Opportunities

According to the International Agency for Research on Cancer (IARC), there were 14.1 million new cases of cancer across the world, and the figure is estimated to reach up to 21.7 million by the end of 2030. This substantial patient volume is the primary driver of the global radiodermatitis market. In addition to that, increasing focus on product innovation as well as advancements in the existing products are also expected to favor the market in the near future. Growing number of private and public healthcare organizations, who are constantly trying to promote the awareness regarding radiodermatitis treatment and management, and rising number of clinical studies to evaluate the efficiency of radiodermatitis treatment are some of the other factors favoring the global radiodermatitis market. 

Based on product, the global radiodermatitis market has been segmented into topical, oral medication, and dressings. While topical segment is sub-segmented into hydrophilic creams, corticosteroids, and others such as antibiotics, oral medical is further divided into corticosteroids and others such as antibiotics and oral analgesics, whereas dressing segment is further categorized into hydrogel, no sting barrier film, hydrocolloid, honey impregnated gauze, silicone coated dressing, and others such as silver leaf dressing and GM-CSF gauze. On the basis of dressing channel, the market has been bifurcated into hospital pharmacy, online store, and retail pharmacy store.

Global Radiodermatitis Market: Regional Outlook

Though the demand for radiodermatitis is growing in all regions across the globe, Asia Pacific currently serves the maximum demand, owing to higher percentage untapped patient-base. A number of emerging economies in the Asian region are situated in tropical region with humid weather conditions, in which the effect of radiation dermatitis is quite high. Extensive collaborations among the key players in order to increase their product portfolio and involvement of well-established pharmaceutical companies in this region on commercialization of their products are also expected to help them increment their shares in this region. 

Companies mentioned in the research report

The report detects Smith & Nephew plc, 3M Healthcare, Acelity, Convatec, Inc., and Molnlycke Health Care as the leading companies in the global radiodermatitis market, collectively accounting for 47% of the shares in 2015. 

Key Segments of the Global Radiodermatitis Market

Global Radiodermatitis Market, by Product

  • Topical
    • Corticosteroids
    • Hydrophilic Creams
    • Others (topical antibiotics)
  • Oral Medication
    • Corticosteroids
    • Other (oral analgesics, antibiotics, etc.)
  • Dressings
    • Hydrogel
    • Hydrocolloid
    • No Sting Barrier Film
    • Honey Impregnated Gauze
    • Silicone Coated Dressing
    • Others (GM-CSF gauze, silver leaf dressing, etc.)

Global Radiodermatitis Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy Store
  • Online Store

Global Radiodermatitis Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top